17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes
- 275 Downloads
Outcomes of melanoma patient treatment remain unsatisfactory despite accessibility of oncoprotein-targeting drugs and immunotherapy. Here, we reported that 17-aminogeldanamycin more potently activated caspase-3/7 in BRAFV600E melanoma cells than geldanamycin, another inhibitor of heat shock protein 90 (HSP90). 17-aminogeldanamycin alleviated self-triggered compensatory increase in HSP70 mRNA level and induced endoplasmic reticulum (ER) stress, which was followed by selective diminution of cytoprotective IRE1α-XBP1s pathway activity of unfolded protein response (UPR), inhibition of ERK1/2 activity and induction of apoptosis. Concomitantly, ATF6/p50 level and expression of PERK-dependent genes, CHOP and BIM, remained unaltered. This might result from an inframe deletion in EIF2AK3 leading to a PERKL21del variant revealed by whole-exome sequencing in melanoma cell lines. 17-aminogeldanamycin exhibited similar activity in NRASQ61R melanoma cells that harbored a heterozygous inactivating variant of NAD(P)H:quinone oxidoreductase 1 (NQO1P187S). In addition, 17-aminogeldanamycin acted cooperatively with trametinib (an inhibitor of MEK1/2) and vemurafenib (an inhibitor of BRAFV600E) in induction of apoptosis in melanoma cell lines as evidenced by in-cell caspase-3/7 activation and PARP cleavage that occurred earlier compared with either drug used alone. As trametinib and vemurafenib did not significantly affect HSP70 and GRP78 transcript levels, cooperation of MEK/BRAFV600E inhibitors and 17-aminogeldanamycin might result from a concurrent inhibition of the RAS/RAF/MEK/ERK cascade and IRE1α-dependent signaling, and cell-intrinsic ER homeostasis can determine the extent of the drug cooperation. Our study indicates that 17-aminogeldanamycin takes several advantages compared with other HSP90-targeting compounds, and can complement activity of BRAF/MEK inhibitors in melanoma cells of different genetic subtypes.
Keywords17-aminogeldanamycin Endoplasmic reticulum stress HSP90 inhibitors IRE-1α Melanoma Targeted therapy
Activating transcription factor 6
BCL-2-interacting mediator of cell death
B-Raf proto-oncogene serine/threonine kinase
C/EBP homologous protein
Department of Molecular Biology of Cancer
Endoplasmic reticulum-associated protein degradation
Extracellular signal-regulated kinase 1/2
Glucose-regulated protein 78/binding immunoglobulin protein
Heat shock protein 70
Heat shock protein 90
Mitogen-activated protein kinase 1/2
Inositol-requiring enzyme 1 alpha
Neuroblastoma RAS viral oncogene homolog
NAD(P)H:quinone oxidoreductase 1
Poly(ADP-ribose) polymerase 1
Protein kinase R-like endoplasmic reticulum kinase
Vemurafenib an inhibitor of BRAFV600E
Trametinib an inhibitor of MEK1/2
Unfolded protein response
- XBP1 (XBP1s)
X-box binding protein 1 (spliced XBP-1)
Genomic classification has been a gauge for clinical management of melanoma patients by using immunotherapy or targeted inhibitors of BRAFV600 and MEK1/2 . However, lack of hot-spot BRAF, RAS, or NF1 driver mutations in the triple wild-type subtype accounting for 6–20% of melanomas [2, 3], and variability of phenotype of patient-derived melanoma cell lines representing the same genetic subtype  enforce combining both genetic and phenotypic traits to achieve more accurately stratification of melanoma patients. In addition, phenotype-based approaches can limit the number of potential therapeutic targets by pointing to master regulators of cell identity as demonstrated by selection of either MEK or HSP90, whose inhibition substantially affected 75% of melanoma cell lines . Heat shock protein 90 (HSP90) is a molecular chaperone involved in a proper folding and multiprotein complex assembly of a myriad of client proteins including several oncoproteins [6, 7], whereas a membrane-bound HSP90 in dying cells facilitates activation of the immune clearance . HSP90 is frequently overexpressed in cancer . Accordingly, expression of HSP90 substantially increases from nevi to melanoma resulting in high HSP90 level in more than 50% of melanoma tumors, and augments with advanced melanoma stage [9, 10]. In addition, also serum levels of HSP90 are higher in melanoma patients than in healthy controls, with median values 49.76 ng/ml versus 27.07 ng/ml, respectively . More interestingly, it has been demonstrated that HSP90 isoform present in melanoma-derived exosomes contributes to creation of a pre-metastatic niche by ‘educating’ bone marrow progenitors .
HSP90 predominantly exerts its function via N-terminal ATPase domain, thus preventing from ATP binding largely interferes with HSP90 activity . Regarding a pleiotropic role of this chaperone, inhibition of HSP90 is associated with an accumulation of improperly folded client proteins, which is followed by induction of endoplasmic reticulum (ER) stress and unfolded protein response (UPR) governed by glucose-regulated protein 78/binding immunoglobulin protein (GRP78/BiP). UPR engages three pathways initiated by the GRP78/BiP release of inositol-requiring enzyme 1 alpha (IRE1α), protein kinase R-like endoplasmic reticulum kinase (PERK) and activating transcription factor 6 (ATF6). These pathways either restore cell homeostasis or promote cell death in case of an excessive proteotoxic stress . In preclinical melanoma studies, structurally different inhibitors of HSP90 produced ER stress , induced apoptosis and reduced tumorigenicity of vemurafenib-resistant cells [16, 17], circumvented mitochondria biogenesis  and mitigated immunosuppressing activity of melanoma cells . Combining XL888 (Exelixis), a non-benzoquinone ATP-competitive inhibitor of HSP90, with targeted inhibitors of the RAS/RAF/MEK/ERK (MAPK) signaling pathway (XL888 + vemurafenib, and XL888 + vemurafenib + cobimetinib) is currently evaluated in phase I clinical trials in patients with unresectable melanoma (clinicaltrials.gov). In a dose escalation trial of XL888 and vemurafenib combination, 15 out of 20 patients (75%) responded to the treatment with a median overall survival of 34.6 months . Resistance to a combination of XL888 and BRAFV600 inhibitor has been recently linked to a CDK2high/MITFhigh phenotype of melanoma cells . Concerning high protein levels of both MITF and CDK2 reported in five out of 12 melanoma cell lines  and the most significant correlation between MITF and CDK2 mRNA levels in melanoma tumor samples compared with other types of cancer , XL888 and BRAFV600 inhibitor combination is likely ineffective in a subset of patients. In the study by Azimi et al., it has been also demonstrated that the same melanoma cell line can exhibit a variable sensitivity to different HSP90 inhibitors . It might result from dissimilar chemical structures of these compounds underlying execution of specific molecular effects as exemplified by BRAFV600E degradation exhibited by benzoquinone inhibitors of HSP90 . Therefore, further research on inhibitors structurally unrelated to XL888 is of interest.
Geldanamycin, a natural benzoquinone inhibitor of the N-terminal ATPase activity of HSP90, was first purified from Streptomyces hydroscopicus, and has been a prototype of a class of anti-cancer agents . Geldanamycin-induced toxicity and low solubility have limited its clinical use . Its derivatives, 17-substituted geldanamycin analogues are less hepatotoxic [25, 26]. 17-aminogeldanamycin is a metabolic product of cytochrome P450 3A4 (CYP3A4)-dependent conversion of 17-N-allylamino-17-demethoxygeldanamycin (tanespimycin) , and exhibits higher water solubility than a parental compound, and higher affinity to HSP90 than a number of other geldanamycin derivatives probably due to additional hydrogen bonds engaging an amine group . It has been demonstrated that 17-aminogeldanamycin is a bioavailable compound upon oral administration [29, 30], and can reduce tumor growth and vessel density in xenografts of gastrointestinal stromal tumors (GIST) . In our previous study on 120 natural agents, we have found that 17-aminogeldanamycin is more cytotoxic than geldanamycin, and both compounds are more potent against melanoma than leukemic cells . In addition, 17-aminogeldanamycin significantly reduces c-MYC transcript level while not affecting the frequency of cells positive for ATP-binding cassette, sub-family B, member 5 (ABCB5) , which is a drug efflux transporter that mediates chemoresistance and marks melanoma-initiating cells . These preliminary results prompted us to evaluate the activity of 17-aminogeldanamycin in melanoma cells more extensively.
Materials and methods
Melanoma cell lines were derived from tumors obtained during surgical interventions. The study was approved by Ethical Commission of Medical University of Lodz, and informed consent was obtained from all patients. Tumor fragments were washed, minced with scissors and incubated in HBSS (Sigma-Aldrich, St Louis, MO, USA) supplemented with 3 mM CaCl2 and 1 mg/ml collagenase IV for few hours at 37 °C. 10 μg/ml DNase I was added and cells were filtered through a 70 μm pore size filter. Cells were cultured in a complete medium (RPMI-1640 supplemented with 10% FBS) for 1 day to remove dead and non-adherent cells. Then, they were transferred to serum-free stem cell medium (SCM) consisting of DMEM/F12 low osmolality medium (Gibco, Paisley, UK), B-27 supplement (Gibco), 10 μg/ml insulin, 1 ng/ml heparin, 10 ng/ml bFGF, 20 ng/ml EGF (BD Biosciences, San Jose, CA, USA), 100 IU/ml penicillin and 100 μg/ml streptomycin [34, 35, 36]. Cell lines were named DMBC12, DMBC21, DMBC28, DMBC29 and DMBC22 (Department of Molecular Biology of Cancer, DMBC). DMBC12, DMBC21, DMBC28 and DMBC29 cells were assigned to the BRAF subtype as they harbored either a homozygous (DMBC12) or heterozygous (DMBC21, DMBC28 and DMBC29) BRAFV600E variant, whereas DMBC22 cells harbored a homozygous Q61R substitution in NRAS . For experiments, melanoma cells were seeded at final density, and drugs were added after 2.5 h.
Vemurafenib and trametinib were purchased from Selleck Chemicals LLC (Houston, TX, USA), geldanamycin from Sigma-Aldrich and 17-aminogeldanamycin from BOC Sciences (Shirley, NY, USA). Chemical formulas of geldanamycin and 17-aminogeldanamycin were prepared using ISIS/Draw (version 2.3). Drug stocks were prepared in DMSO. For experiments, drugs were dissolved in the culture medium to final concentrations as following: 5 μM vemurafenib (PLX), 50 nM trametinib (TRA), 0,1 and 0,4 μM geldanamycin (GEL) and 17-aminogeldanamycin (AG).
Whole-exome sequencing was performed as described previously . Raw data are available at ArrayExpress and European Nucleotide Archive (ENA) under the numbers E-MTAB-6978 and ERP109743, respectively. Functional effects of amino acid substitutions were predicted in silico by the Polyphen-2 software (genetics.bwh.harvard.edu/pph2/index.shtml). The Polyphen-2-based predictions were classified as benign (scores 0.000–0.449), possibly damaging (scores 0.450–0.959) or probably damaging (scores 0.960–1.000).
A time-lapse fluorescent microscopy
Melanoma cells were grown in 96-well plates (8 × 103 cells/well) and treated with drugs at indicated concentrations and IncuCyte Caspase-3/7 Apoptosis Assay Reagent at 4 μM for 3 days. Activation of caspase-3/7 was monitored every 3 h by using a time-lapse fluorescence microscope system IncuCyte ZOOM (IncuCyte, Essen Bioscience). Data were analyzed using the IncuCyte Zoom original software. Percent of cells with active caspase-3/7 was calculated by dividing the percentages of confluence of apoptotic cells by the percentages of confluence of all cells at particular time points.
Acid phosphatase activity assay
Acid phosphatase activity was assessed to determine a number of viable melanoma cells. Melanoma cells were grown for 0, 24, 48 and 72 h, then the plates were centrifuged and medium was replaced with assay buffer as described previously . The absorbance values were measured using a microplate reader Infinite M200Pro (Tecan, Salzburg, Austria).
Cells were incubated with drugs for 24 and 48 h, then collected, trypsinized and stained with Annexin V-FLUOS Staining Kit (Roche, Manheim, Germany) for 15 min. Flow cytometric data were acquired with FACSVerse (BD Biosciences), and analyzed using BD FACSuite.
Cell lysate preparation and Western blotting
Melanoma cells were lysed in RIPA buffer containing 50 mmol/l Tris–HCl pH 8.0, 150 mmol/l NaCl, 1% TritonX-100, 0.5% sodium deoxycholate, 0.1% SDS supplemented with freshly added protease and phosphatase inhibitors (Sigma-Aldrich). Cell lysates were diluted in 2 × Laemmli buffer and protein samples (15 μg) were loaded on standard 7% SDS–polyacrylamide gel. After electrophoresis, the proteins were transferred onto Immobilon-P PVDF membrane (Millipore, Billerica, MA, USA) followed by incubation in a blocking solution: 5% nonfat milk in PBS-Tween 0.05% or 5% phospho-BLOCKER (Cell Biolabs, San Diego, CA, USA) in PBS-Tween 0.05%. Primary antibodies detecting PARP, ATF6, IRE1α, GRP78 and p53 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), p-IRE1α from Abcam (Cambridge, UK), β-actin from Sigma-Aldrich, p-ERK1/2 (Thr202/Tyr204) and ERK1/2 from Cell Signaling Technology (Danvers, MA, USA). Secondary HRP-conjugated anti-mouse or anti-rabbit antibodies (Santa Cruz Biotechnology) and Pierce ECL Western Blotting Substrate (Pierce, Rockford, IL, USA) were used to visualize proteins on the X-ray film (Foton-Bis, Bydgoszcz, Poland) or by using ChemiDoc Imaging System (Biorad). The quantification of the Western blotting data was performed by using ImageJ software.
RNA isolation, cDNA synthesis and quantitative RT-PCR (qRT-PCR)
Total RNA isolation, cDNA synthesis and amplification procedures were extensively described elsewhere . Primer sequences are shown in the Online Resource 1. To calculate the relative expression of target genes versus a reference gene RPS17, a mathematical model including an efficiency correction was used.
Graphs are presented as mean ± SD. To calculate statistical significance of differences, Statistica v.13 software was used. Normality of a sample distribution was assessed by the Shapiro–Wilk test. The Levene’s test was used to determine equality of variances. The unpaired t test was used to compare two samples with normal distribution and equal variances. In case of different sample size or when n = 2, Mann–Whitney U test was used. To compare three samples with normal distribution and equal variances, ANOVA was used. The differences were considered significant if p ≤ 0.05.
17-Aminogeldanamycin (AG) is more effective than geldanamycin (GEL) in caspase-3/7 activation in melanoma cells
AG at 0.4 μM reduces viability and inhibits ERK1/2 activity in BRAFV600E melanoma cells
AG transiently increases mRNA levels of HSP70 and GRP78
AG selectively diminishes activity of IRE1α-dependent pathway of UPR
AG-mediated upregulation of GRP78 expression suggested induction of ER stress. AG slightly increased IRE1α activity after 4 h (Fig. 3d), but levels of both total and phosphorylated IRE1α (p-IRE1α) were markedly reduced after additional 20 h of incubation with a drug (Fig. 3d). As a consequence, level of spliced XBP1 (XBP1s) mRNA was significantly diminished in all melanoma cell lines (Fig. 3e). Importantly, GEL at the same concentration did not affect the transcript level of XBP1s in DMBC21 and DMBC29 cells (Online Resource 4) that exhibited the largest decrease in XBP1s mRNA level in response to AG (Fig. 3e). Apart from its evident effect on the IRE1α-XBP1s pathway activity, 0.4 μM AG did not markedly affect level of a nuclear form of ATF6 (p50) (Fig. 3f), and did not significantly induce CHOP and BIM expression (Fig. 3g) encoding for executioners of PERK-dependent apoptosis. For that reason, we assessed p53/BIK-dependent route as an alternative pathway of apoptosis induced in response to prolonged ER stress . AG at 0.4 μM did not substantially alter the protein level of p53, except for an increase in DMBC12 cells already after 4 h (Online Resource 5a). This was associated with an insignificant effect of AG on BIK transcript level in all melanoma cell lines (Online Resource 5b). To elucidate lack of apparent mechanism of ER stress-triggered apoptosis, we used whole-exome sequencing data  to determine the mutation status of genes encoding components of the UPR cascades. We found that PERK-dependent pathway might be affected by an inframe deletion in EIF2AK3 leading to a PERKL21del variant that was harbored in all melanoma cell lines (Online Resource 2), although genes encoding downstream components of the PERK signaling, ATF4 and eIF2α, either harbored alteration leading to a variant predicted as benign or were unaltered (Online Resource 2).
AG cooperates with inhibitors of BRAFV600E and MEK1/2 in induction of apoptosis
AG is also effective against NRASQ61R melanoma cells
In the present study, we have demonstrated that 17-aminogeldanamycin perturbates ER homeostasis, predominantly by interfering with activity of IRE1α-dependent pathway, and induces apoptosis in melanoma cells of the BRAFV600E and NRASQ61R subtypes. 17-aminogeldanamycin takes several advantages over geldanamycin and other geldanamycin derivatives as supported by previously published and present results showing that 17-aminogeldanamycin (i) is more potent than geldanamycin against melanoma cells; (ii) exerts anti-melanoma activity at lower concentrations compared with IC50 values for other geldanamycin analogues assessed in different human cancer cell lines , and (iii) attenuates self-triggered increase in HSP70 transcript level.
17-Aminogeldanamycin alleviates self-triggered upregulation of HSP70 expression
It has been demonstrated that N-terminal inhibitors of HSP90 activate heat shock factor-1 (HSF-1) to upregulate expression of other chaperones including HSP70 and HSP27 [37, 39, 40]. This cell response contributes to development of resistance to HSP90 inhibitors [41, 42] as compensatory chaperones can remain at increased levels in cells incubated with geldanamycin, its analogues [43, 44, 45] and XL888, a geldanamycin-unrelated inhibitor of HSP90 . Here, we have shown that 17-aminogeldanamycin upregulates HSP70 expression, which returns to baseline mRNA level in both BRAFV600E and NRASQ61R melanoma cell lines. It is consistent with other results showing insignificant alterations in the protein level of HSP70 in GIST cell lysates after 17-aminogeldanamycin administration . This suggests that attenuation of self-induced upregulation of HSP70 expression is rather drug-specific than cell type-dependent, and might be crucial for a high activity of 17-aminogeldanamycin in melanoma cells.
17-Aminogeldanamycin selectively inhibits cytoprotective IRE1α-XBP1s signaling pathway of UPR
Upregulation of HSP70 expression following inhibition of HSP90 compensates for HSP90 function and deters from activation of prolonged ER stress and UPR, and induction of apoptosis emerging from an increased burden of misfolded proteins . Disturbances in the execution of UPR support adaptation of cancer cells to proteotoxic stress . In melanoma, UPR and other stress-attenuating signaling pathways are hyperactivated during tumor progression and cell response to therapy [49, 50]. They engage different anti-apoptotic proteins  and microphthalmia-associated transcription factor (MITF) . Increasing evidence suggests that targeting the ER stress and UPR programs can be a promising anti-melanoma strategy [53, 54], also against resistant cells due to the contribution of GRP78/BiP to ERK1/2 reactivation . In the present study, we have found that 17-aminogeldanamycin induces ER stress as evidenced by a transient increase in GRP78 transcript level and a slight activation of IRE1α already after 4 h. IRE1α autophosphorylation followed by its dimerization leads to the excision of a 26-nt intron from XBP1 transcript and a generation of XBP1s mRNA translated into XBP1, a transcription factor that regulates expression of ER stress-attenuating genes [56, 57]. XBP1 has been implicated in the regulation of melanoma cell proliferation by activating inteleukin-6/STAT3 pathway  in addition to its critical role in melanoma cell survival during ER stress . As both IRE1α and ATF6 can upregulate expression of GRP78 in melanoma , the contribution of IRE1α to the increase in GRP78 mRNA level is more likely because ATF6 activity remained unaltered following 17-aminogeldanamycin treatment. More importantly, while IRE1α activation could be an acute cytoprotective response of melanoma cells to 17-aminogeldanamycin, prolonged incubation with this compound led to a substantial diminution of both activity and protein level of IRE1α, probably due to a chaperoning role of HSP90 on IRE1α . This effect can be specific for particular HSP90 inhibitors because tanespimycin inhibited XBP1s generation without abrogating IRE1α protein level even when used in higher concentration (1 µM)  than 0.4 µM 17-aminogeldanamycin used in our study. Therefore, 17-aminogeldanamycin is capable to reduce IRE1α activity and also, by leading to IRE1α degradation, to prevent from undesired activation of cytoprotective IRE1α signaling, which might be valuable considering 17-aminogeldanamycin as a part of combined treatment.
17-Aminogeldanamycin induces apoptosis in melanoma cells harboring PERKL21del and NQO1P187S variants
ER stress-induced apoptosis has been commonly attributed to PERK signaling-dependent upregulation of CHOP and BIM expression , although CHOP-deficient cells also undergo apoptosis in response to ER stress inducers . Alternatively, p53-dependent suppression of GRP78 mRNA translation and induction of BIK expression can induce apoptosis . In the present study, we have demonstrated that apoptosis induced by 17-aminogeldanamycin unlikely depends on any of these pathways. PERK-dependent signaling might be affected due to an inframe deletion in EIF2AK3 leading to a PERKL21del variant that was found in all melanoma cell lines. A PERKL21del variant has been already reported in one tumor sample excised from a patient before treatment with vemurafenib . It needs to be elucidated how deletion of Leu21 affects PERK structure and activity. On the other hand, an increase in p53 level was found exclusively in one cell line and this was not associated with either decrease in GRP78 protein level (Fig. 3c) or upregulation of BIK expression (Online Resource 5), despite transcriptionally active p53 in all melanoma cell lines . Thus, while 17-aminogeldanamycin apparently diminishes activity of cytoprotective IRE1α-XBP1s axis and induces apoptosis in melanoma cells, specific mediators of cell death need to be determined.
Cell sensitivity to geldanamycin derivatives correlates with expression of NAD(P)H:quinone oxidoreductase 1 (NQO1) , and NQO1-mediated quinone-to-hydroquinone conversion of geldanamycin and its analogues enhances activity of these compounds because of increased hydrogen bonding of hydroquinone derivatives . It has also been shown that a P187S variant of NQO1 has a reduced activity compared with wild-type NQO1 , but genetic alterations affecting a His80 residue in NQO1 can compensate for P187S substitution . In our study, a heterozygous NQO1P187S variant (rs1800566) was harbored exclusively in DMBC22 cells. As DMBC22 cells lack additional alterations in NQO1, NQO1P187S variant might contribute to a delayed pro-apoptotic response of DMBC22 cells to 17-aminogeldanamycin compared with the response of cell lines harboring wild-type NQO1. However, it has been demonstrated that the affinity of 17-aminogeldanamycin to purified HSP90 is not considerably enhanced upon reduction to the hydroquinone , and cell response to 17-aminogeldanamycin is not associated with NQO1 protein level . It suggests that activity of 17-aminogeldanamycin is at least partially independent of NQO1 that can be advantageous because a loss of NQO1 expression and acquisition of an inactive NQO1P187S variant have been demonstrated as causative factors in development of resistance to tanespimycin in melanoma and glioblastoma cells .
17-Aminogeldanamycin and inhibitors of the RAS/RAF/MEK signaling cascade cooperatively induce apoptosis
17-Aminogeldanamycin is a more potent HSP90 inhibitor than geldanamycin against melanoma cells, and exerts previously unidentified activities including diminution of self-triggered upregulation of HSP70 expression and selective inhibition of cytoprotective IRE1α-XBP1s axis of unfolded protein response. In addition, 17-aminogeldanamycin cooperates with inhibitors of the MAPK signaling pathway in apoptosis induction that might be exploited in BRAFV600E and NRASQ61R melanomas.
This study was funded by National Science Centre (Poland), Grant No. 2014/15/B/NZ7/00947. We thank Dr. Anna Gajos-Michniewicz for cell culture propagation and helpful discussion, and Ewa Lewandowska for excellent administrative and technical support.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Begiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, Hoon D, Karakousis G, Liu Q, Mitra N, Petrelli NJ, Schuchter L, Shannan B, Shields CL, Wargo J, Wenz B, Wilson MA, Xiao M, Xu W, Xu X, Yin X, Zhang NR, Davies MA, Herlyn M, Nathanson KL (2017) Genetic and genomic characterization of 462 melanoma patient-derived xenografts, tumor biopsies, and cell lines. Cell Rep 21(7):1936–1952. https://doi.org/10.1016/j.celrep.2017.10.052 Google Scholar
- 12.Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, Nitadori-Hoshino A, Hoffman C, Badal K, Garcia BA, Callahan MK, Yuan J, Martins VR, Skog J, Kaplan RN, Brady MS, Wolchok JD, Chapman PB, Kang Y, Bromberg J, Lyden D (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18(6):883–891. https://doi.org/10.1038/nm.2753 Google Scholar
- 14.Almanza A, Carlesso A, Chintha C, Creedican S, Doultsinos D, Leuzzi B, Luís A, McCarthy N, Montibeller L, More S, Papaioannou A, Püschel F, Sassano ML, Skoko J, Agostinis P, deBelleroche J, Eriksson LA, Fulda S, Gorman AM, Healy S, Kozlov A, Muñoz-Pinedo C, Rehm M, Chevet E, Samali A (2018) Endoplasmic reticulum stress signalling—from basic mechanisms to clinical applications. FEBS J 286(2):241–278. https://doi.org/10.1111/febs.14608 Google Scholar
- 16.Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS (2012) The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18(9):2502–2514. https://doi.org/10.1158/1078-0432.CCR-11-2612 Google Scholar
- 17.Smyth T, Paraiso KHT, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, Sondak VK, Thompson NT, Azab M, Lyons JF, Smalley KSM, Wallis NG (2014) Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 13(12):2793–2804. https://doi.org/10.1158/1535-7163.MCT-14-0452 Google Scholar
- 18.Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, Xiao M, Randell S, Sproesser K, Xu W, Liu J, Karakousis GC, Schuchter LM, Gangadhar TC, Amaravadi RK, Gu M, Xu C, Ghosh A, Xu W, Tian T, Zhang J, Zha S, Liu Q, Brafford P, Weeraratna A, Davies MA, Wargo JA, Avadhani NG, Lu Y, Mills GB, Altieri DC, Flaherty KT, Herlyn M (2016) Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834–1856. https://doi.org/10.1172/JCI82661 Google Scholar
- 20.Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM (2018) Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E-mutant melanoma. Clin Cancer Res 24(22):5516–5524. https://doi.org/10.1158/1078-0432.CCR-18-0565 Google Scholar
- 21.Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Brage ES, Altun M, Uhlen M, Maddalo G (2018) Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors. Mol Syst Biol 14(3):e7858. https://doi.org/10.15252/msb.20177858 Google Scholar
- 22.Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M (2013) The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS ONE 8(3):e59588. https://doi.org/10.1371/journal.pone.0059588 Google Scholar
- 25.Samuni Y, Ishii H, Hyodo F, Samuni U, Krishna MC, Goldstein S, Mitchell JB (2010) Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. Free Radic Biol Med 48(11):1559–1563. https://doi.org/10.1016/j.freeradbiomed.2010.03.001 Google Scholar
- 27.Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman CJ (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Oncol 23(6):1078–1087. https://doi.org/10.1200/JCO.2005.09.119 Google Scholar
- 29.Lee J, Grenier L, Holson E, Slocum K, Coco J, Ge J, Normant E, Hoyt J, Lim A, Cushing J, Sydor J, Wright J (2008) IPI-493, a potent, orally bioavailable HSP90 inhibitor of the ansamycin class. Abstract, EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer TherapeuticsGoogle Scholar
- 30.Senzer NN, Mendelson D, Weekes C, Rosen L, LoRusso P, Just R, Smith D, Ritchie E, DeLucia D, Quigley T, Dunbar J, Schmalbach T, Cortes J (2011) Safety, tolerability, and pharmacokinetics of IPI-493, an oral Hsp90 inhibitor, in patients with advanced cancers. Mol Cancer Ther 11(11 Suppl):Abstract nr B101Google Scholar
- 31.Floris G, Sciot R, Wozniak A, Van Looy T, Wellens J, Faa G, Normant E, Debiec-Rychter M, Schöffski P (2011) The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res 17(17):5604–5614. https://doi.org/10.1158/1078-0432.CCR-11-0562 Google Scholar
- 33.Wilson BJ, Saab KR, Ma J, Schatton T, Putz P, Zhan Q, Murohy GF, Gasser M, Waaga-Gasser AM, Frank NY, Frank MH (2014) ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res 74(15):4196–4207. https://doi.org/10.1158/0008-5472.CAN-14-0582 Google Scholar
- 39.Neckers L, Blagg B, Haystead T, Trepel JB, Whitesell L, Picard D (2018) Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. Cell Stress Chaperones 23(4):467–482. https://doi.org/10.1007/s12192-018-0877-2 Google Scholar
- 40.Kijima T, Prince TL, Tigue ML, Yim KH, Schwartz H, Beebe K, Lee S, Budzynski MA, Williams H, Trepel JB, Sistonen L, Calderwood S, Neckers L (2018) HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation. Sci Rep 8(1):6976. https://doi.org/10.1038/s41598-018-25404-w Google Scholar
- 46.Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS (2014) Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics 13(7):1844–1854. https://doi.org/10.1074/mcp.M113.037424 Google Scholar
- 53.Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C, Abbe P, Amdouni H, Passeron T, Hofman V, Mograbi B, Dabert-Gay AS, Debayle D, Alcor D, Rabhi N, Annicotte JS, Héliot L, Gonzalez-Pisfil M, Robert C, Moréra S, Vigouroux A, Gual P, Ali MMU, Bertolotto C, Hofman P, Ballotti R, Benhida R, Rocchi S (2016) Compounds triggering ER stress exert anti-melanoma effects and overcome BRAF inhibitor resistance. Cancer Cell 29(6):805–819. https://doi.org/10.1016/j.ccell.2016.04.013 Google Scholar
- 54.Eigner K, Filik Y, Mark F, Schütz B, Klambauer G, Moriggl R, Hengstschläger M, Stangl H, Mikula M, Röhrl C (2017) The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone. Sci Rep 7(1):17498. https://doi.org/10.1038/s41598-017-17888-9 Google Scholar
- 55.Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK (2018) ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-18-0348 Google Scholar
- 62.Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC (2012) Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood 119(24):5772–5781. https://doi.org/10.1182/blood-2011-07-366633 Google Scholar
- 64.Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D, Dermatologic Cooperative Oncology Group of Germany (DeCOG) (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 1:94–109Google Scholar
- 65.Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O’Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570–575. https://doi.org/10.1038/nature11005 Google Scholar
- 66.Chang CH, Drechsel DA, Kitson RR, Siegel D, You Q, Backos DS, Ju C, Moody CJ, Ross D (2014) 19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity. Mol Pharmacol 85(6):849–857. https://doi.org/10.1124/mol.113.090654 Google Scholar
- 71.Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM, Smalley KS (2013) Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther 12(6):901–912. https://doi.org/10.1158/1535-7163.MCT-12-1003 Google Scholar
- 72.Corazzari M, Rapino F, Ciccosanti F, Giglio P, Antonioli M, Conti B, Fimia GM, Lovat PE, Piacentini M (2015) Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma. Cell Death Differ 22(6):946–958. https://doi.org/10.1038/cdd.2014.183 Google Scholar
- 74.Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F (2013) Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal 6(260):ra7. https://doi.org/10.1126/scisignal.2003057 Google Scholar
- 75.Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 124(3):1406–1417. https://doi.org/10.1172/JCI70454 Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.